271 related articles for article (PubMed ID: 26618921)
1. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
2. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
3. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
4. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
5. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin: An Antibiotic with Important Biologic Effects.
DuPont HL
Mini Rev Med Chem; 2015; 16(3):200-5. PubMed ID: 26202192
[TBL] [Abstract][Full Text] [Related]
7. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.
Lopetuso LR; Petito V; Scaldaferri F; Gasbarrini A
Mini Rev Med Chem; 2015; 16(3):179-85. PubMed ID: 26643042
[TBL] [Abstract][Full Text] [Related]
9. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.
Ponziani FR; Scaldaferri F; Petito V; Paroni Sterbini F; Pecere S; Lopetuso LR; Palladini A; Gerardi V; Masucci L; Pompili M; Cammarota G; Sanguinetti M; Gasbarrini A
Dig Dis; 2016; 34(3):269-78. PubMed ID: 27027301
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
11. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea.
Ericsson CD
Drug Saf; 2006; 29(3):201-7. PubMed ID: 16524320
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin: beyond the traditional antibiotic activity.
Calanni F; Renzulli C; Barbanti M; Viscomi GC
J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.
Xu D; Gao J; Gillilland M; Wu X; Song I; Kao JY; Owyang C
Gastroenterology; 2014 Feb; 146(2):484-96.e4. PubMed ID: 24161699
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Harris LA; Baffy N
Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]